Enhancing AI Research Paper Analysis: Methodology Component Extraction using Factored Transformer-based Sequence Modeling Approach

Research in scientific disciplines evolves, often rapidly, over time with the emergence of novel methodologies and their associated terminologies. While methodologies themselves being conceptual in nature and rather difficult to automatically extract and characterise, in this paper, we seek to develop supervised models for automatic extraction of the names of the various constituents of a methodology, e.g., `R-CNN', `ELMo' etc. The main research challenge for this task is effectively modeling the contexts around these methodology component names in a few-shot or even a zero-shot setting. The main contributions of this paper towards effectively identifying new evolving scientific methodology names are as follows: i) we propose a factored approach to sequence modeling, which leverages a broad-level category information of methodology domains, e.g., `NLP', `RL' etc.; ii) to demonstrate the feasibility of our proposed approach of identifying methodology component names under a practical setting of fast evolving AI literature, we conduct experiments following a simulated chronological setup (newer methodologies not seen during the training process); iii) our experiments demonstrate that the factored approach outperforms state-of-the-art baselines by margins of up to 9.257\% for the methodology extraction task with the few-shot setup.

Deep Graph Convolutional Network and LSTM based approach for predicting drug-target binding affinity

Development of new drugs is an expensive and time-consuming process. Due to the world-wide SARS-CoV-2 outbreak, it is essential that new drugs for SARS-CoV-2 are developed as soon as possible. Drug repurposing techniques can reduce the time span needed to develop new drugs by probing the list of existing FDA-approved drugs and their properties to reuse them for combating the new disease. We propose a novel architecture DeepGLSTM, which is a Graph Convolutional network and LSTM based method that predicts binding affinity values between the FDA-approved drugs and the viral proteins of SARS-CoV-2. Our proposed model has been trained on Davis, KIBA (Kinase Inhibitor Bioactivity), DTC (Drug Target Commons), Metz, ToxCast and STITCH datasets. We use our novel architecture to predict a Combined Score (calculated using Davis and KIBA score) of 2,304 FDA-approved drugs against 5 viral proteins. On the basis of the Combined Score, we prepare a list of the top-18 drugs with the highest binding affinity for 5 viral proteins present in SARS-CoV-2. Subsequently, this list may be used for the creation of new useful drugs.